Overview

Effects of Levosimendan in Patients Eligible for Aortic Valve Replacement With Left Ventricular Hypertrophy

Status:
Terminated
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
This is a clinical, randomised, double-blinded study in which patients eligible for aortic valve replacement are enrolled. Patients receive infusion of either levosimendan or placebo 4 hours prior to surgery and until the end of surgery.
Phase:
Phase 4
Details
Lead Sponsor:
University of Aarhus
Treatments:
Simendan